Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant—a systematic review
Authors:
- 27 August 2019
- journal article
- review article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (4) , 779-789
Abstract
Objectives: In severe rapidly progressive SSc, autologous haematopoietic stem cell transplantation (AHSCT) allows significant improvements in overall and event-free survival. We undertook this study to identify, appraise and synthesize the evidence on health-related quality of life (HRQoL) before and after AHSCT for SSc. Methods: We performed a systematic review of the literature, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, in PubMed and ScienceDirect from database inception to 1 February 2019. All articles with original HRQoL data were selected. Results: The search identified 1080 articles, of which 8 were selected: 3 unblinded randomized controlled trials [American Scleroderma Stem Cell versus Immune Suppression Trial (ASSIST), Autologous Stem Cell Transplantation International Scleroderma, Scleroderma: Cyclophosphamide or Transplantation), 3 uncontrolled phase I or II trials and 2 cohort studies. HRQoL data from 289 SSc patients treated with AHSCT and 125 treated with intravenous CYC as a comparator with median 1.25–4.5 years follow-up were included. HRQoL was evaluated with the HAQ Disability Index (HAQ-DI; 275 patients), the 36-item Short Form Health Survey (SF-36; 249 patients) and the European Quality of Life 5-Dimensions questionnaire (EQ-5D; 138 patients). The quality of the studies was moderate to low. AHSCT was associated with significant improvement in the HAQ-DI (P = 0.02–<0.001), SF-36 Physical Component Summary score (P = 0.02–<0.0001) and EQ-5D index-based utility score (P < 0.001). The SF-36 Mental Component Summary score improved in the ASSIST (n = 19) and one small retrospective cohort (n = 30 patients, P = 0.005) but did not improve significantly in 2 randomized controlled trials (n = 200 patients, P = 0.1–0.91). Conclusion: AHSCT in severe SSc patients is associated with significant and durable improvement in physical HRQoL.Keywords
This publication has 35 references indexed in Scilit:
- Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysisThe Lancet, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow TransplantationBone Marrow Transplantation, 2011
- Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centresAnnals of the Rheumatic Diseases, 2011
- Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosisRheumatology, 2010
- Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung StudyRheumatology, 2009
- Quality of Life in Patients with Systemic Sclerosis Compared to the General Population and Patients with Other Chronic ConditionsThe Journal of Rheumatology, 2009
- High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot studyBlood, 2007
- Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ)Clinical Rheumatology, 2004
- Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin diseaseAnnals of the Rheumatic Diseases, 2001